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SUMMARY — In order to study the nigrostriatal pathway, we obtained the rotatory behavior 
model in male Wistar rats by electrolytic lesion of the left lateral hypothalamic region. 
Animals thus lesioned displayed rotations toward the same side of lesion when apomorphine 
was administered, a result in disagreement with what has been obtained in the model with 
6-hydroxydopamine lesion. The administration of PLG alone was not followed by rotatory 
behavior but when the compound was administered in low doses (0.25 to 1mg/kg) simul-
taneously with apomorphine to animals previously submitted to REM sleep deprivation, a 
significant increase in the number of rotations was observed in comparison with controls 
and groups receiving higher doses of PLG. These results indicate that PLG may act as, a 
modulator on dopamine receptors in the striatum. 
Ação de prolil-leucil-gliclnamida (PLG) na via nigroestriatal do rato. 
RESUMO — No intuito de estudar a via nigroestriatal, produzimos uma lesão na região 
hipotalâmica lateral de ratos Wistar. Os animais passavam a apresentar comportamento 
rotatório para o mesmo lado da lesão. A administração isolada do PLG não induziu o com-
portamento rotatório. Entretanto, com doses baixas do composto, concomitantemente à admi-
nistração de apomorfina em animais previamente submetidos à privação de sono REM, 
observou-se aumento no número de rotações auando comparado ao grupo controle e aos 
grupos aue receberam doses altas de PLG. Estes achados sugerem que o PLG age como 
um modulador sobre os receptores dopaminérgicos do estriado. 
The observation that melanocyte stimulating hormone (MSH) has a deleterious 
effect on Parkinson's d i s e a s e 1 3 was the start point for a series of investigations, both 
experimental 7,21,23,24,33 and clinical 4,5,16,17,20
 0 f the effects of a synthetic tripeptide, 
prolyl-leucyl-glycinamide (PLG) on Parkinson's disease. The rationale for these 
studies is that PLG shares many properties with the melanocyte inhibiting factor 
(MIF). The investigations mentioned showed that PLG may be useful in Parkinson's 
disease, a benefit that may be enhanced by association with dopaminergic agonists. 
These studies, however, did not clarify the mechanism of action of PLG, so that 
we decided to further investigate on this issue, by studing the action of this compound 
on the rotatory model of the rat 31.32. it is postulated that the destruction of the 
nigrostriatal pathway leaves hypersensitized postsynaptic dopaminergic receptors due 
to denervation. When a dopaminergic agent is administered, the unbalance causes 
a rotatory behavior, the animal turning toward the same side or contralateral to the 
lesions, according with its pre or postsynaptic actions. 
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MATERIAL AN3> METHODS 
Male albino Wistar rats were used. The animals were 3 to 5 months old, weighted 
250 to 350 grams and were kept in steady conditions of light and temperature, with water 
and food ad lib. Each animal was anesthesized with methyleugenol 10, 250mg:/kg i.p. A 
stereotaxically directed lesion was made by the passage of a cathodic current of 2mA for 
10 seconds in the left lateral hypothalamic region, according to previously described parame­
ters 30. After the surgery the animals were kept in individual cages, and 24 hours later 
submitted to behavioral observation for selection regarding further experiments. Selection 
criteria were spontaneous rotation of 360° and walking in circles, independent of the number 
of rotations as long as they proceeded in the same direction. On the 7 th day after the 
surgery. 2mg/kg of apomorphine was administered in order to submit the animals to a new 
selection, using the same criteria described above and observing them up to 30 minutes 
after the drug. Only animals exhibiting rotatory behavior on this second selection were 
utilized. PLG was synthesized in the Department of Biophysics of the Escola Paulista de 
Medicina, and apomorphine was purchased from Sigma Laboratories. Both drugs were 
diluted in normal saline and iniected intra-peritoneally. 
In the first series of experiments 6 groups with 5 rats in each were used. On the 15th 
day after surgery a control group received saline, and the others received PLG in different 
doses as shown in table 1, followed by observation of rotatory behavioral for 60 minutes. In 
the second series of experiments 7 groups with 5 rats in each were used. On the 30th day 
after surgery all animals were submitted to REM sleep deprivation (REM SD) by the 
inverted flower pot technique l for 72 hours. Immediately after the REM SD a control group 
received saline, two other groups 0.25 or 0.50 mg/kg of apomorphine, and the remaining four 
groups received different doses of PLG followed by 0.2&mg/kg of apomorphine as shown 
in table 2. Then, the animals had their behavior observed for a maximum period of 30 
minutes. Once started the rotation behavior, the number of rotations was determined during 
10 minutes. 
RESULTS 
The rotatory behavior toward the same side of the lesion occurred spontaneously for 
3 or 4 days after surgery and reappeared after administration of apomorphine in the 7th day. 
In experiment 1 no animal in any of the groups displayed rotatory behavior after 
administration of PLG. In the groups receiving the highest doses (4, 8 and 16 mg/kg) 
diminished motor activity was seen, associated to sleepiness and piloerection. 
In experiment 2 no rotatory behavior was seen in groups A, B, C and G. In groups 
D, E and F rotatory behavior was present, with highest number of rotations seen in group 
E (Table 3). 
Analysis of variance showed significant difference among the groups of experiment 2 
(p<0.05). Student t test showed a significant difference (p<0.05) when groups A, B, C and 
G were compared to groups D and E. A difference at the same level was seen when the 
last two groups were compared one to the other. No difference was seen when cwnpajlRS 
any group with group F. 
COMMENTS 
Placing the electrolytic lesion in the lateral hypothalamic region was based in 
the demonstration of ascending nigrostriatal dopaminergic pathways running near this 
area 2 . In the model thus obtained the animals displayed rotatory behavior ipsilateral 
to the lesion, in disagreement with the original model developed by Ungerstedt 31.32 
who injected 6-hydroxydopamine in the nigrostriatal pathway for neuronal destruction. 
An explanation for the difference is that the rotatory behavior is a result of dopa-
minergic stimulation, both pre and postsynaptic, on the intact side, as demonstrated 
by previous studies with dopaminergic agents in animals with electrolytic lesions of 
the substantia nigra or lateral hypothalamus 11.12,25. it was suggested that, as the 
electrolytic lesion is non-specific, it could destroy other inputs necessary to build up 
dopaminergic stimulus in the striatum, or even damage an afferent striato-pallidal 
pathway mediating rotatory behavior. Another explanation could be that dopamine 
receptors become hyposensitive after electrolytic l e s i o n 1 2 . Other researchers, working 
with 6-hydroxydopamine, have shown that the direction of rotatory behavior in res-
ponse to apomorphine depends on the exact place of the lesion, being toward the 
same side in lesions at the lateral substantia nigra and contralateral in lesions at the 
medial substantia n i g r a 2 9 . 
The administration of PLG alone in increasing doses was not followed by 
rotatory behavior in the model utilized by us, the same being found in previous studies 
suggesting that there is not a direct effect on the nigrostrjatal receptors 5,7,21,26,27, 
The possibility that after electrolytic lesion direct dopaminergic agonists act on the 
intact s i d e 2 2 prompted us to search for a procedure that could render these receptors 
more sensitive, enhancing the action of PLG and thus improving its effect. We know 
from previous studies 9-30 that REM SD is a simple noninvasive method for the induc-
tion of supersensitivity of postsynaptic dopaminergic receptors. In the striatal area 
supersensitivity could be obtained by REM SD in rats with bilateral lesions of the 
lateral hypothalamic a r e a 3 . 
In REM SD animals (experiment 2) the administration of either apomorphine 
or PLG alone was not followed by rotatory behavior, but the association of both 
drugs in low doses brought rotations to the same side of the lesion, a behavior 
that disappeared with higher doses of PLG. These findings suggest that the action 
of PLG is dependent of the presence of dopaminergic agonist (apomorphine, in this 
study) and of hypersensibility of receptors (induced by REM SD, in this study). 
The pattern of our results, an inverted U-shaped dose-response relationship, was 
seen by others using PLG in different doses in apomorphine-induced stereotypy 1 9 , 
haloperidol-induced catalepsy 18 and stress-induced antinociceptive effect 
The observation that PLG has no effect on the binding of ( 3 H) spiroperidol 
but enhances the binding of ( 3 H) apomorphine was taken as an evidence of pre-
synapt ic action 8, but the doses were lower than the effective ones of our study. 
The absence of response to PLG alone was also seen in clinical trials 5.6.14 and in 
other experimental studies 7.27. 
An explanation for our results could be that higher doses of PLG might interfere 
on the motor behavior due to sleepiness and slowness of motor activity. However, 
it is our impression that PLG acts as a modulator, interacting with dopaminergic 
agents or modifying the receptors affinity. This hypothesis is strenghtened by the 
demonstration that PLG enhances the binding of selectice high-affinity agonist 
n-propyl-nor-apomorphine to D2 receptors in bovine striatal membranes, by enhan-
cement of interaction of these receptors with guanine nucleotide regulatory proteins 28. 
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